AJMC.com Managed Markets Network Adam C. Cuker, MD, MS, of the University of Pennsylvania, described the “4T” score, a widely used system that allows clinicians to evaluate the timing a degree of thrombocytopenia and whether it might be caused by heparin . Dr Cuker said this is one the ...
The Oncology Report Key clinical point: Cancer patients who have incidental pulmonary emboli discovered during imaging should receive chronic anticoagulation with low-molecular-weight heparin . Major finding: The risk for a recurrent venous thromboembolism was 12% in ...
U-T San Diego Patients given ISIS FXIrx experienced less thrombosis without increased bleeding, compared to those given enoxaparin, a drug made from heparin . A total o...
MedPage Today SAN FRANCISCO -- Treatment of deep vein thromboses (DVT) with the low-molecular-weight heparin tinzaparin (Innohep) lessened the risk of recurrent blood clots in cancer patients, along with significantly reducing symptomatic DVT and clinically relevant ...
WhaTech In terms of the proposed/ongoing projects, however, it is projected that the heparin API in China will achieve an additional capacity of more than 20 trillion units by 2015, when China's total capacity will exceed 30 trillion units, accounting for ...
In-PharmaTechnologist.com Heparin production may be moving back to Europe according to the EFCG, which cited the opening of Pharma Action's processing plant as an indication that API buyers value quality and compliance throughout the supply chain. and more »
The Pharmaceutical Journal The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a class 4 drug alert for heparin sodium IV flush solution 100 IU/ml distributed by Kent Pharmaceuticals Ltd on behalf of Fannin (UK) Limited. This is due to an error on cartons ...
Newswise (press release) Newswise — Hamilton, ON (Nov. 18, 2014) – McMaster University researchers have found new evidence that suggests patients with a history of adver...
RTT News NovoTek, a Beijing-based pharmaceutical and medical device business development company, owns the exclusive sales and marketing rights for the Company's PIFA Heparin /PF4 Rapid Assay products in China. The firm plans to deliver the order by this ...
